Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | YTHDC1 | Q96MU7 | 7/20 | 0.35 |
| ▸ | XDH | P47989 | 1/20 | 0.33 |
| ▸ | SCN10A | Q9Y5Y9 | 2/20 | 0.33 |
| ▸ | PDE2A | O00408 | 1/20 | 0.33 |
| ▸ | NNMT | P40261 | 1/20 | 0.33 |
| ▸ | CFTR | P13569 | 1/20 | 0.32 |
| ▸ | SCN1A | P35498 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.32 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.32 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.32 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.32 |
| ▸ | EGFR | P00533 | 1/20 | 0.32 |
| ▸ | KDR | P35968 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | GLA | P06280 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13828343 | 0.81 | PDPK1 (0.38) | POLBNNMT | |
| SCHEMBL13826193 | 0.80 | LMNA (0.48) | LMNAPOLBCFTRKDM4EALDH1A1 | |
| SCHEMBL13828345 | 0.80 | GFER (0.30) | POLB | |
| SCHEMBL13828406 | 0.80 | POLB (0.33) | POLBNNMTKDM4EALDH1A1MAPT | |
| SCHEMBL13828336 | 0.80 | GFER (0.33) | POLB | |
| SCHEMBL15868896 | 0.76 | MEN1 (0.33) | — | |
| SCHEMBL15868912 | 0.76 | KDM4E (0.38) | LMNAKDM4EGAA | |
| SCHEMBL11292615 | 0.75 | POLB (0.46) | LMNAPOLBCFTRKDM4EALDH1A1 | |
| SCHEMBL30712146 | 0.72 | YTHDC1 (0.40) | LMNAYTHDC1XDHPDE2AALDH1A1 | |
| SCHEMBL15760956 | 0.72 | POLB (0.41) | LMNAPOLBYTHDC1NNMTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180110783-A1 | NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES | RHIZEN PHARMACEUTICALS SA (CH) | 2018-04-26 | — | — | US | disclosed |
| US-9775841-B2 | Compounds as modulators of protein kinases | RHIZEN PHARMACEUTICALS SA (CH) | 2017-10-03 | — | — | US | disclosed |
| US-9775841-B2 | Compounds as modulators of protein kinases | RHIZEN PHARMACEUTICALS SA (CH) | 2017-10-03 | — | — | US | disclosed |
| US-9212192-B2 | Bicyclic carboxamide inhibitors of kinases | ABBVIE INC. (US) | 2015-12-15 | — | — | US | disclosed |
| US-9212192-B2 | Bicyclic carboxamide inhibitors of kinases | ABBVIE INC. (US) | 2015-12-15 | — | — | US | disclosed |
| US-20150320752-A1 | NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES | RHIZEN PHARMACEUTICALS AG (CH) | 2015-11-12 | — | — | US | disclosed |
| US-20140194418-A1 | BICYCLIC CARBOXAMIDE INHIBITORS OF KINASES | ABBVIE INC. (US) | 2014-07-10 | — | — | US | disclosed |
| US-20140194418-A1 | BICYCLIC CARBOXAMIDE INHIBITORS OF KINASES | ABBVIE INC. (US) | 2014-07-10 | — | — | US | disclosed |
| US-20140171429-A1 | BICYCLIC INHIBITORS OF ALK | ABBVIE INC. (US) | 2014-06-19 | — | — | US | disclosed |
| US-20140171429-A1 | BICYCLIC INHIBITORS OF ALK | ABBVIE INC. (US) | 2014-06-19 | — | — | US | disclosed |
| US-20120289496-A1 | NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES | RHIZEN PHARMACEUTICALS SA (CH) | 2012-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150320752-A1 | NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES | PRKCA, PRKCH, PRKCB | LMNA 2205/4885POLB 2194/4885YTHDC1 4770/4885 |
| US-20120289496-A1 | NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES | PRKCA, PRKCH, PRKCB | LMNA 2205/4885POLB 2194/4885YTHDC1 4770/4885 |
| US-20140171429-A1 | BICYCLIC INHIBITORS OF ALK | ALK, ACVR1, ACVR1B | LMNA 575/4885POLB 1446/4885YTHDC1 3720/4885 |
| US-20180110783-A1 | NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES | PRKCA, PRKCH, PRKCB | LMNA 2205/4885POLB 2194/4885YTHDC1 4770/4885 |
| US-20140194418-A1 | BICYCLIC CARBOXAMIDE INHIBITORS OF KINASES | ALK, BRAF, BMX | LMNA 1850/4885POLB 1605/4885YTHDC1 3098/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.